Targeted Therapeutics in Melanoma (Record no. 101604)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03394nam a22004575i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-1-61779-407-0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220083251.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 111214s2012 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781617794070 |
| -- | 978-1-61779-407-0 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-61779-407-0 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC254-282 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.994 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gajewski, Thomas F. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Targeted Therapeutics in Melanoma |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | edited by Thomas F. Gajewski, F. Stephen Hodi. |
| 264 #1 - | |
| -- | New York, NY : |
| -- | Springer New York, |
| -- | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XIV, 377p. 27 illus., 22 illus. in color. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | Current Clinical Oncology |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Molecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine & Public Health. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer Research. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hodi, F. Stephen. |
| Relator term | editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9781617794063 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Current Clinical Oncology |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-1-61779-407-0 |
| 912 ## - | |
| -- | ZDB-2-SME |
No items available.